These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 9347380)

  • 41. Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: an open-label study.
    Miyaoka T; Furuya M; Yasuda H; Hayashida M; Nishida A; Inagaki T; Horiguchi J
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):761-4. PubMed ID: 18201810
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Trazodone: a double-blind, placebo-controlled, randomized study of its effects in patients with erectile dysfunction without major organic findings.
    Enzlin P; Vanderschueren D; Bonte L; Vanderborght W; Declercq G; Demyttenaere K
    Int J Impot Res; 2000 Aug; 12(4):223-8. PubMed ID: 11079363
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial.
    Abbasi SH; Behpournia H; Ghoreshi A; Salehi B; Raznahan M; Rezazadeh SA; Rezaei F; Akhondzadeh S
    Schizophr Res; 2010 Feb; 116(2-3):101-6. PubMed ID: 19959338
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nilvadipine is effective for chronic schizophrenia in a double-blind placebo-controlled study. off.
    Yamada K; Kanba S; Ashikari I; Ohnishi K; Yagi G; Asai M
    J Clin Psychopharmacol; 1996 Dec; 16(6):437-9. PubMed ID: 8959468
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of tardive dyskinesia with donepezil: a pilot study.
    Caroff SN; Campbell EC; Havey J; Sullivan KA; Mann SC; Gallop R
    J Clin Psychiatry; 2001 Oct; 62(10):772-5. PubMed ID: 11816865
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Confirmation of the neurophysiologically predicted therapeutic effects of trazodone on its target symptoms depression, anxiety and insomnia by postmarketing clinical studies with a controlled-release formulation in depressed outpatients.
    Saletu-Zyhlarz GM; Anderer P; Arnold O; Saletu B
    Neuropsychobiology; 2003; 48(4):194-208. PubMed ID: 14673218
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
    Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical effectiveness of the Kampo medicine kamishoyosan for adjunctive treatment of tardive dyskinesia in patients with schizophrenia: a 16-week open trial.
    Lee JG; Shin BS; Lee YC; Park SW; Kim YH
    Psychiatry Clin Neurosci; 2007 Oct; 61(5):509-14. PubMed ID: 17875029
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study.
    Lerner V; Miodownik C; Kaptsan A; Bersudsky Y; Libov I; Sela BA; Witztum E
    J Clin Psychiatry; 2007 Nov; 68(11):1648-54. PubMed ID: 18052557
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
    Berk M; Ichim C; Brook S
    Int Clin Psychopharmacol; 2001 Mar; 16(2):87-92. PubMed ID: 11236073
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
    Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W
    J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of mianserin in chronic schizophrenia.
    Mizuki Y; Kajimura N; Kai S; Suetsugi M; Ushijima I; Yamada M
    Prog Neuropsychopharmacol Biol Psychiatry; 1992 Jul; 16(4):517-28. PubMed ID: 1641495
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Experiences with doxepin and trazodone in the therapy with outpatients suffering from depression.
    Pöldinger W
    Psychopathology; 1984; 17 Suppl 2():30-6. PubMed ID: 6371876
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
    Josiassen RC; Kane JM; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):61-68. PubMed ID: 28839341
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Therapeutic measures in tardive dyskinesia].
    Tegeler J; Wöller W
    Fortschr Neurol Psychiatr; 1983 Jun; 51(6):203-26. PubMed ID: 6136457
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative double-blind study on efficacy and side-effects of trazodone, nomifensine, mianserin in elderly patients.
    Scardigli G; Jans G
    Adv Biochem Psychopharmacol; 1982; 32():229-36. PubMed ID: 7046366
    [No Abstract]   [Full Text] [Related]  

  • 57. A controlled study of the efficacy and safety of mianserin and amitriptyline in depressive inpatients.
    Möller HJ; Kasper S; Müller H; Kissling W; Fuger J; Ruhrmann S
    Pharmacopsychiatry; 1995 Nov; 28(6):249-52. PubMed ID: 8773291
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
    Correll CU; Josiassen RC; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):53-60. PubMed ID: 28839340
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Severe hyperthermia during tetrabenazine therapy for tardive dyskinesia.
    Stevens E; Roman A; Houa M; Razavi D; Jaspar N
    Intensive Care Med; 1998 Apr; 24(4):369-71. PubMed ID: 9609418
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment of neuroleptic-induced akathisia with the 5-HT2 antagonist mianserin. Double-blind, placebo-controlled study.
    Poyurovsky M; Shardorodsky M; Fuchs C; Schneidman M; Weizman A
    Br J Psychiatry; 1999 Mar; 174():238-42. PubMed ID: 10448449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.